Physiomics awarded further contract by Numab Therapeutics
Data science company Physiomics said on Monday that it had been awarded a further contract by an existing client.
Physiomics said Numab Therapeutics had tapped it to work on a project that involves Pharmacokinetic-Pharmacodynamic modelling in support of one of Numab's oncology assets entering the clinic and will help inform dose and scheduling decisions.
Chief executive Peter Sargent said: "We are thrilled to have this opportunity to continue working with and supporting Numab on this asset through its preclinical stages as it heads into the clinic.
"Along with the project we announced with them in August 2023, this new project is a testament to the continued support we provide and the great relationships we've built".
As of 1415 GMT, Physiomics shares were up 8.28% at 1.57p.
Reporting by Iain Gilbert at Sharecast.com
Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news and we may not share the views of the author or publisher. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.
The value of investments can fall and you may get back less than you invested.